Home › Salivary Gland Cancer › New Jersey
Salivary Gland Cancer clinical trials in New Jersey
3 studies for Salivary Gland Cancer are looking for participants at sites in New Jersey.
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05408845Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Memorial Sloan Kettering Monmouth, Middletown
- Memorial Sloan Kettering Bergen, Montvale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT04620187VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Englewood Hospital and Medical Center (site 202), Englewood
- Summit Medical Group (site 205), Florham Park
- Atlantic Health System, Morristown Medical Center (site 124), Morristown
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Dec 11, 2025 · NCT03556228From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.